Introduction
Methods
Patients and Samples
Quantitative real-time PCR
Flow cytometry
Cytometric bead array
Laboratory data
Statistical analysis
Results
Association between CX3CR1, LOX-1, CD163, and PD-1 expression and clinical data before and after surgery
Variables | N or median (range) | Variables | N or median (range) | |
---|---|---|---|---|
Age [years old] | 72 (43-89) | Hisological type | ||
Sex | differentiated/ undifferentiated adenoca. | 22/ 19 | ||
Male/ Female | 31/10 | Tumor Locationb
| ||
Body Mass Index [kg/m2] | 21.97 (16.59-33.58) | E/ U/ M/ L/ Other | 3/ 8/ 11/ 18/ 1 | |
Other cancer history | 14 (34.1%) | pT categorya
| ||
cT-categorya
| 1-2/ 3-4 | 16/ 25 | ||
1-2/ 3-4 | 13/ 28 | pN-categorya
| ||
cN-categorya
| 0/ 1-3 | 19/ 22 | ||
0/ 1-3 | 20/ 21 | pStagea
| ||
cStagea
| I-II/ III-IV | 26/ 15 | ||
I-II/ III-IV | 21/ 20 | Ly | present/ absent | 18/ 23 |
Comorbidities (present, %) | 35 (85.4%) | Vsss | present/ absent | 17/ 24 |
Diabetes Mellitus | 14 (34.1%) | Surgical operation | ||
Cardiac disease | 3 (7.31%) | Open/ Laparoscopy | 31/ 10 | |
Renal disorder | 1 (2.44%) | TG/ DG+PGb
| 14/ 27 | |
Pulmonary disorder | 6 (14.6%) | Lymph nodes dissection (D1/ 1+/ 2) | 5/ 11/ 25 | |
Hepatic disorder | 6 (14.6%) | Bleeding [mL] | 210 (5-1700) | |
Operation time [min.] | 259 (106-607) | |||
Anesthesia time [min.] | 294 (148-640) | |||
Duration of hospitalization [days] | 13 (8-64) |
CX3CR1 | |||||||
---|---|---|---|---|---|---|---|
Opening | Closure | ||||||
low (n = 31 ) | high (n = 10) |
P† | low (n = 17) | high (n = 24) |
P† | ||
Sex | Male/ Female | 24/ 7 | 7/ 3 | 0.683 | 11/ 6 | 20/ 4 | 0.270 |
Age(years-old) | 72.0 (69.5-76.0) | 69.5 (65.3-77.3) | 0.438 | 69.6 (65.0-73.0) | 73.3 (69.0-78.3) | 0.295 | |
Tumor size (mm) | 45.0 (30.0-80.5) | 42.5 (23.0-54.5) | 0.523 | 38.0 (30.0-50.0) | 50.0 (33.8-86.3) | 0.076 | |
Comorbidities | absent/ present | 4/ 27 | 2/ 8 | 0.622 | 3/ 14 | 3/ 21 | 0.679 |
Other cancer history | absent/ present | 18/ 13 | 9/ 1 | 0.123 | 12/ 5 | 15/ 9 | 0.742 |
Preoperative NLR | 2.66 (1.92-3.39) | 1.98 (1.70-3.05) | 0.235 | 1.79 (1.64-3.29) | 2.75 (2.19-3.49) | 0.037* | |
Postoperative NLR | 6.65 (4.47-9.01) | 6.65 (5.44-9.32) | 0.574 | 5.56 (3.81-6.65) | 7.38 (5.72-11.7) | 0.005* | |
Preoperative PLR | 113 (70.1-137) | 78.1 (56.4-104) | 0.118 | 56.0 (51.2-101) | 124 (90.2-165) | <0.001* | |
Postoperative PLR | 177 (128-236) | 183 (97.1-261) | 0.777 | 99.3 (79.0-174) | 191 (175-491) | <0.001* | |
CRP POD3 | 12.1 (4.34-19.6) | 12.2 (9.92-21.3) | 0.649 | 6.29 (3.24-14.3) | 14.2 (10.1-23.8) | 0.010* | |
cT stagea
| T1-2/ 3-4 | 9/ 22 | 4/ 6 | 0.698 | 7/ 10 | 6/ 18 | 0.322 |
cN stagea
| N0/ 1-3 | 15/ 16 | 5/ 5 | 1 | 9/ 8 | 11/ 13 | 1 |
cStagea
| Stage I-II/ III-IV | 16/ 15 | 5/ 5 | 1 | 8/ 9 | 13/ 11 | 0.756 |
Histological type | differentiated/ undifferentiated | 18/ 13 | 4/ 6 | 0.469 | 10/ 7 | 12/ 12 | 0.752 |
pT stagea
| T1-2/ 3-4 | 10/ 21 | 6/ 4 | 0.15 | 10/ 7 | 6/ 18 | 0.051 |
pN number | 2.00 (0.00-3.00) | 0.00 (0.00-1.75) | 0.361 | 0.00 (0.00-3.00) | 2.00 (0.00-3.00) | 0.194 | |
pN stagea
| N0/ 1-3 | 13/ 18 | 6/ 4 | 0.469 | 11/ 6 | 8/ 16 | 0.062 |
pStagea
| Stage I-II/ III-IV | 20/ 11 | 7/ 3 | 1 | 13/ 4 | 14/ 10 | 0.321 |
Lymphatic invasion | absent/ present | 16/ 15 | 7/ 3 | 0.467 | 12/ 5 | 11/ 13 | 0.201 |
Venous invasion | absent/ present | 17/ 14 | 7/ 3 | 0.48 | 12/ 5 | 12/ 12 | 0.217 |
Operative approach | open/ laparoscopic | 25/ 6 | 6/ 4 | 0.222 | 12/ 5 | 19/ 5 | 0.714 |
Operative procedure | DG or PG/ TG | 19/ 12 | 8/ 2 | 0.447 | 13/ 4 | 14/ 10 | 0.321 |
Lymphadenectomy | D1 or 1+/ D2 | 10/ 21 | 6/ 4 | 0.150 | 10/ 7 | 6/ 18 | 0.051 |
Operative time (min) | 251 (213-289) | 300 (239-324) | 0.092 | 236 (219-306) | 261 (225-305) | 0.634 | |
Anesthesia time (min) | 289 (246-322) | 314 (275-369) | 0.141 | 277 (265-331) | 296 (264-339) | 0.525 | |
Bleeding (mL) | 200 (50-380) | 440 (35-844) | 0.370 | 80 (20-510) | 265 (73-410) | 0.283 | |
Comlplications | absent/ present | 20/ 11 | 6/ 4 | 1 | 12/ 5 | 14/ 10 | 0.519 |
Duration of hospitalization (days) | 13.0 (10-18.5) | 12.0 (11-18.3) | 0.867 | 11.0 (9-14) | 13.5 (11-21) | 0.039* | |
Adjuvant chemotherapy | absent/ present | 13/ 18 | 6/ 4 | 0.469 | 11/ 6 | 8/ 16 | 0.062 |
Recurrence | absent/ present | 23/ 8 | 5/ 5 | 0.241 | 15/ 2 | 13/ 11 | 0.039* |
Recurrent style (local/ lymphatic/ hematogenous/ dissemination) | 0/ 2/ 3/ 5 | 1/ 0/ 1/ 2 | 0.566 | 0/ 0/ 0/ 2 | 1/ 2/ 4/ 5 | 0.692 |
CX3CR1 change 'Opening' to 'Closure' | ||||||
---|---|---|---|---|---|---|
high-high (n=5) | low-high (n=19) | high-low (n=5) | low-low (n=12) |
P† | ||
Sex | Male/ Female | 1/ 4 | 3/ 16 | 2/ 3 | 4/ 8 | 0.573 |
Age(years-old) | 75.0 (67.0-78.0) | 72.0 (69.5-77.5) | 65.0 (57.0-72.0) | 71.5 (70.3-73.8) | 0.542 | |
Tumor size (mm) | 56.0 (45.0-70.0) | 50.0 (32.5-87.5) | 38.0 (18.0-40.0) | 37.5 (30.0-56.3) | 0.258 | |
Comorbidities | absent/ present | 1/ 4 | 2/ 17 | 1/ 4 | 2/ 10 | 0.913 |
Other cancer history | absent/ present | 5/ 0 | 10/ 9 | 4/ 1 | 8/ 4 | 0.211 |
Preoperative NLR | 2.20 (2.16-3.34) | 2.85 (2.28-3.52) | 1.69 (1.58-1.72) | 2.14 (1.75-3.30) | 0.123 | |
Postoperative NLR | 7.43 (5.41-25.7) | 7.32 (5.83-10.1) | 5.88 (5.56-8.44) | 4.13 (3.54-6.14) | 0.025* | |
Preoperative PLR | 111 (80.4-131) | 125 (93.7-178) | 53.5 (40.6-65.0) | 64.0 (51.2-115) | 0.004* | |
Postoperative PLR | 186 (182-560) | 195 (173-399) | 89.7 (79.0-186) | 113 (83.8-167) | 0.010* | |
CRP POD3 | 20.5 (10.1-23.2) | 13.9 (9.84-23.9) | 9.90 (8.35-14.3) | 4.34 (2.94-3.0) | 0.065 | |
cT stagea
| T1-2/ 3-4 | 2/ 3 | 4/ 15 | 2/ 3 | 5/ 7 | 0.601 |
cN stagea
| N0/ 1-3 | 3/ 2 | 15/ 4 | 4/ 1 | 9/ 3 | 0.842 |
cStagea
| Stage I-II/ III-IV | 2/ 3 | 11/ 8 | 3/ 2 | 5/ 7 | 0.757 |
Histological type | differentiated/ undifferentiated | 1/ 4 | 11/ 8 | 3/ 2 | 7/ 5 | 0.457 |
pT stagea
| T1-2/ 3-4 | 2/ 3 | 4/ 15 | 4/ 1 | 6/ 6 | 0.082 |
pN number | 1.0 (0.0-2.0) | 2.0 (0.0-3.0) | 0.0 (0.0-0.0) | 0.0 (0.0-3.25) | 0.498 | |
pN stagea
| N0/ 1-3 | 4/ 1 | 10/ 9 | 4/ 1 | 8/ 4 | 0.533 |
pStagea
| Stage I-II/ III-IV | 3/ 2 | 11/ 8 | 4/ 1 | 9/ 3 | 0.682 |
Lymphatic invasion | absent/ present | 4/ 1 | 7/ 12 | 3/ 2 | 9/ 3 | 0.122 |
Venous invasion | absent/ present | 3/ 2 | 9/ 10 | 4/ 1 | 8/ 4 | 0.521 |
Operative approach | open/ laparoscopic | 2/ 3 | 3/ 16 | 2/ 3 | 3/ 9 | 0.555 |
Operative procedure | DG or PG/ TG | 4/ 1 | 10/ 9 | 4/ 1 | 9/ 3 | 0.421 |
Lymphadenectomy | D1 or 1+/ D2 | 3/ 2 | 3/ 16 | 3/ 2 | 7/ 5 | 0.045* |
Operative time (min) | 294 (261-322) | 259 (213-286) | 306 (230-325) | 234 (211-283) | 0.353 | |
Anesthesia time (min) | 321 (306-370) | 294 (246-324) | 339 (273-365) | 291 (248-333) | 0.469 | |
Bleeding (mL) | 370 (50.0-615) | 230 (110-375) | 510 (20.0-920) | 70.0 (13.8-395) | 0.434 | |
Comlplications | absent/ present | 3/ 2 | 11/ 8 | 3/ 2 | 9/ 3 | 0.803 |
Duration of hospitalization (days) | 13 (11-20) | 14 (11.5-21.5) | 11 (11-13) | 10 (9.0-14) | 0.184 | |
Adjuvant chemotherapy | absent/ present | 2/ 3 | 6/ 13 | 4/ 1 | 7/ 5 | 0.194 |
Recurrence | absent/ present | 2/ 3 | 12/ 7 | 4/ 1 | 11/ 1 | 0.135 |
Recurrent style (local/ lymphatic/ hematogenous/ dissemination) | 1/ 0/ 1/ 1 | 0/ 2/ 3/ 4 | 0/ 0/ 0/ 1 | 0/ 0/ 0/ 1 | 0.771 |
LOX-1 | CD163 | PD-1 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Closure | Closure | Closure | ||||||||
low (n = 29) | high (n = 12) |
P† | low (n = 24) | high (n = 13) |
P† | low (n=27) | high (n=11) |
P† | ||
Sex | Male/ Female | 22/ 7 | 9/ 3 | 1 | 18/ 6 | 10/ 3 | 1 | 22/ 5 | 8/ 3 | 0.667 |
Age(years-old) | 71.0 (65.0-73.0) | 72.5 (69.0-78.3) | 0.295 | 72.0 (69.8-76.8) | 71.0 (67.0-73.0) | 0.202 | 71.0 (67.5-72.5) | 75.0 (72.0-79.0) | 0.032* | |
Tumor size (mm) | 40.0 (30.0-65.0) | 50.0 (40.0-87.0) | 0.240 | 40.0 (28.0-61.3) | 45.0 (30.0-56.0) | 0.556 | 40.0 (27.5-62.5) | 45.0 (32.5-63.0) | 0.640 | |
Comorbidities | absent/ present | 3/ 26 | 3/ 9 | 0.334 | 4/ 20 | 2/ 11 | 1 | 4/ 23 | 2/ 9 | 1 |
Other cancer history | absent/ present | 20/ 9 | 7/ 5 | 0.719 | 16/ 8 | 8/ 5 | 1 | 17/ 10 | 8/ 3 | 0.714 |
Preoperative NLR | 2.17 (1.79-2.97) | 3.23 (2.54-4.45) | 0.037* | 2.17 (1.79-3.01) | 3.12 (2.20-3.97) | 0.124 | 2.36 (1.76-3.31) | 2.24 (2.07-4.46) | 0.376 | |
Postoperative NLR | 5.97 (4.28-8.33) | 8.48 (5.33-23.3) | 0.140 | 5.96 (4.53-8.54) | 6.91 (4.66-15.9) | 0.455 | 5.97 (4.32-8.63) | 7.43 (4.95-16.6) | 0.247 | |
PreoperativePLR | 78.0 (53.6-124) | 132 (108-189) | 0.003* | 79.2 (54.2-128) | 123 (92.9-132) | 0.102 | 82.3 (53.9-129) | 111 (86.6-131) | 0.274 | |
Postoperative PLR | 164 (90.8-203) | 201 (180-568) | 0.018* | 160 (90.5-207) | 186 (177-560) | 0.102 | 157 (90.2-252) | 186 (173-407) | 0.111 | |
cT stagea
| T1-2/ 3-4 | 11/ 18 | 2/ 10 | 0.276 | 10/ 14 | 2/ 11 | 0.149 | 10/ 17 | 3/ 8 | 0.714 |
cN stagea
| N0/ 1-3 | 16/ 13 | 4/ 8 | 0.306 | 13/ 11 | 6/ 7 | 0.737 | 12/ 15 | 7/ 4 | 0.476 |
cStagea
| Stage I-II/ III-IV | 17/ 12 | 4/ 8 | 0.181 | 14/ 10 | 6/ 7 | 0.512 | 14/ 13 | 6/ 5 | 1 |
CRP POD3 | 11.5 (4.67-17.5) | 14.2 (7.12-23.3) | 0.547 | 11.37 (5.43-17.5) | 12.1 (3.24-23.2) | 0.987 | 12.2 (4.64-19.6) | 12.1 (10.7-21.9) | 0.394 | |
Histological type | differentiated/ undifferentiated | 14/ 15 | 8/ 4 | 0.325 | 12/ 12 | 7/ 6 | 1 | 15/ 12 | 5/ 6 | 0.724 |
pT stagea
| T1-2/ 3-4 | 12/ 17 | 4/ 8 | 0.734 | 11/ 13 | 4/ 9 | 0.491 | 11/ 16 | 4/ 7 | 1 |
pN number | 0.00 (0.00-3.00) | 2.50 (1.75-3.25) | 0.065 | 0.00 (0.00-4.25) | 2.00 (0.00-2.00) | 0.973 | 1.00 (0.00-3.00) | 1.00 (0.00-4.00) | 0.785 | |
pN stagea
| N0/ 1-3 | 17/ 12 | 2/ 10 | 0.019* | 13/ 11 | 5/ 8 | 0.495 | 13/ 14 | 5/ 6 | 1 |
pStagea
| Stage I-II/ III-IV | 20/ 9 | 7/ 5 | 0.719 | 17/ 7 | 9/ 4 | 1 | 19/ 8 | 6/ 5 | 0.457 |
Lymphatic invasion | absent/ present | 19/ 10 | 4/ 8 | 0.087 | 14/ 10 | 8/ 5 | 0.460 | 15/ 12 | 7/ 4 | 0.729 |
Venous invasion | absent/ present | 20/ 9 | 4/ 8 | 0.045* | 13/ 11 | 9/ 4 | 0.638 | 17/ 10 | 6/ 5 | 0.722 |
Operative approach | open/ laparoscopic | 20/ 9 | 6/ 6 | 0.300 | 16/ 8 | 11/ 2 | 0.440 | 19/ 8 | 7/ 4 | 0.714 |
Operative procedure | DG or PG/ TG | 20/ 9 | 7/ 5 | 0.719 | 19/ 5 | 6/ 7 | 0.067 | 7/ 20 | 2/ 9 | 1 |
Lymphadenectomy | D1 or 1+/ D2 | 14/ 15 | 2/ 10 | 0.084 | 9/ 15 | 6/ 7 | 0.730 | 10/ 17 | 6/ 5 | 0.471 |
Operative time (min) | 251 (223-309) | 264 (196-297) | 0.764 | 243 (214-303) | 268 (251-306) | 0.382 | 236 (213-304) | 267 (246-308) | 0.385 | |
Anesthesia time (min) | 294 (268-352) | 292 (233-315) | 0.422 | 274 (250-333) | 312 (279-335) | 0.259 | 277 (250-322) | 306 (282-344) | 0.311 | |
Bleeding (mL) | 140 (20-380) | 270 (142-651) | 0.105 | 100 (20-373) | 380 (150-750) | 0.0502 | 210 (45-470) | 150 (40-683) | 0.735 | |
Complications | absent/ present | 20/ 9 | 6/ 6 | 0.300 | 17/ 7 | 8/ 5 | 0.716 | 17/ 10 | 7/ 4 | 1 |
Duration of hospitalization (days) | 11.0 (10-18) | 14.0 (13-20) | 0.084 | 11.5 (10-14) | 14 (11-20) | 0.291 | 12.0 (10-18) | 13.0 (11-23) | 0.457 | |
Adjuvant chemotherapy | absent/ present | 16/ 13 | 3/ 9 | 0.098 | 14/ 10 | 4/ 9 | 0.17 | 11/ 16 | 7/ 4 | 0.288 |
Recurrence | absent/ present | 24/ 5 | 5/ 7 | 0.020* | 20/ 4 | 7/ 6 | 0.118 | 21/ 6 | 7/ 4 | 0.432 |
Recurrent style (local/ lymphatic/ hematogenous/ dissemination) | 1/ 1/ 1/ 2 | 0/ 1/ 3/ 5 | 0.629 | 1/ 1/ 2/ 2 | 0/ 0/ 1/ 5 | 0.318 | 0/ 0/ 1/ 5 | 1/ 1/ 2/ 2 | 0.318 |